RxDoctor Payments DataLook up a doctor →

Paul Griggs, MD

Ophthalmology · Seattle, WANPI 1578584264

Payments from drug & device makers

$62,209in general payments, 2019–2025

Across 160 payments — averaging $388.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spark Therapeutics, Inc.$46K
  • Astellas Pharma US Inc$3K
  • AbbVie$2K
  • Vertex$2K
  • BD$983
  • Harrow Eye, LLC$966
  • plus $7K from 22 others

What the payments were for

  • Consulting fees$9,10815%
  • Speaking & faculty fees$43,21569%
  • Travel & lodging$2,2224%
  • Food & beverage$7,63312%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,209 in reported general payments places this provider in the 90th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$2,884,395
Medicare patients
1,022
Services billed
43,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine86$63,641
LumiganBimatoprost37$19,353
CombiganBrimonidine Tartrate/Timolol44$11,667
Latanoprost825$9,167
XiidraLifitegrast11$7,380
Difluprednate60$7,064
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$6,508
RhopressaNetarsudil Mesylate17$6,172
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat258$4,822
Prednisolone Acetate106$4,086
Brimonidine Tartrate147$4,012
Timolol Maleate173$1,801
Tobramycin-DexamethasoneTobramycin/Dexamethasone47$1,727
Dorzolamide-TimololDorzolamide/Timolol/Pf11$902
Dorzolamide Hcl30$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$2,375$94,661167 claims
Bausch & Lomb Americas Inc.Xiidra$422$7,38011 claims
Aerie Pharmaceuticals, Inc.Rhopressa$137$6,17217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →